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ABSTRACT. Lipoxygenase-pathway metabolites of arachidonic acid are produced in pancreatic islets. They 
are are implicated in insulin release, since nonselective inhibitors of lipoxygenases inhibit glucose-induced 
insulin release. We studied the interplay in insulin release between glucose and selected icosanoids formed 
in 5-, 12- and 15-lipoxygenase pathways. Effects on immunoreactive insulin release of 10’ to 1O-6 
12-(R)-HETE, 12-(S)-HETE, hepoxilin As, lipoxin Bq, LTB4 or LTC4 were tested individually in 30-min 
incubations of freshly isolated young adult Wistar rat pancreatic islets, in the presence of 5.6 mM or 23 mM 
glucose. Basal insulin release (at 5.6 mM glucose) was stimulated by LTC4 and hepoxilin A3 (304% and 234% 
of controls at 5.6 mM glucose alone, respectively), inhibited by 12-(S)-HPETE (56%), and was not affected 
by 12-(R)-HETE, 12-(S)-HETE, lipoxin B4 or LTB4 (ill%, 105%, 106% and 136%, respectively). Insulin 
release evoked by 23 mM glucose (190-320%) was inhibited (50-145%) by all icosanoids tested, except LTC4 
(162%). We conclude that, among the lipoxygenase products tested, only leukotrienes and hepoxilin are 
candidates for a tonic-stimulatory influence on basal insulin release. Since glucose promotes icosanoid 
formation in islets, the observed inhibition of glucose-induced insulin release by lipoxygenase products 
suggests the existence of a negative-feedback system. 
INTRODUCTION 
In many mammalian tissues, 5-, 12- and 15- 
lipoxygenases exist, which convert arachidonic acid 
(5,8,11,14-icosatetraenoic acid) into hydroperoxy- 
and hydroxy-icosatetraenoic acids, leukotrienes, 
hepoxilins and lipoxins. Icosanoids formed in the 
lipoxygenase pathways are of potential interest 
in regards to pancreatic islet function, in that non- 
selective inhibitors of lipoxygenases consistently 
attenuate stimulated insulin release in vitro (l-6). 
In search for the identity of the putative insulin 
secretagogue, individual exogenous lipoxygenase- 
pathway products have been administered to the 
pancreas or pancreatic islets. Among the hydroxy- 
icosatetraenoic acids (HETEs), Yamamoto et al (7) 
found that 5-HETE stimulated basal insulin release; 
on the other hand, 12-HETE and 15-HETE in- 
hibited glucose-induced insulin release. Metz et al 
(4) did not observe any effect of 1ZHETE in neo- 
natal rat islets; yet, Turk et al (1) reported that 
the attenuation of glucose-induced insulin release 
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evoked by a lipoxygenase inhibitor, icosatetraynoic 
acid (ETYA), was reversed partially by the addition 
of 12-HETE. Among the hydroperoxy- 
icosatetraenoic acids (HPETEs), 12-HPETE and 
15-HPETE stimulated insulin release in neonatal, 
but not in adult rat islets (8). Yamamoto et al (7) 
found that 15-HPETE inhibited glucose-induced in- 
sulin release. An epoxide formed in the 
12-lipoxygenase pathway, 8-hydroxy-11, 12-epoxy- 
icosatrienoic acid (hepoxilin A3) stimulated insulin 
release in the presence of 10 mM glucose (9). We 
reported that 5, 12-dihydroxy-icosatetraenoic acid 
(leukotriene Bq, LTBJ,5-hydroxy-6-S-glutathionyl- 
icosatetraenoic acid (LTCJ, and.to a lesser extent 
5-hydroxy-6-S-cysteinylglycinyl- icosateraenoic acid 
(LTD4) and 5-hydroxy-6-S-cysteinyl- icosatetraenoic 
acid (LTE,J stimulated insulin secretion from the 
isolated, perfused rat pancreas (10). Metz et al (4) 
found that an epoxy-derivative of LTA4 stimulated 
insulin release from neonatal rat islets. 
Evidence has been sought for the biosynthesis of 
lipoxygenase-pathway products of arachidonate in 
pancreatic islets. A major icosanoid formed from 
arachidonate in islets is 12-HETE (11, 12). Pace-As- 
ciak and Martin (9) reported that rat islets produce 
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hepoxilin As. We provided preliminary evidence for washed with Krebs-Ringer-Hepes buffer (KRH), 
the production of leukotrienes (13); although Turk and preincubated in 200 p KRH containing 5.6 mM 
et al (12, 14) failed to confirm this finding. glucose and 0.1% bovine serum albumin, 
A potential interplay between the lipoxygenase 
pathway products and glucose in islets is suggested. 
First, an increase in ambient glucose concentration 
leads to increased production of these icosanoids in 
islets (11, 15). Second, the attenuation of insulin 
secretion with inhibitors of lipoxygenases has been 
demonstrated mostly with glucose-induced insulin 
release. The present study represents a unifying ef- 
fort to establish which icosanoids formed in the 
three lipoxygenase pathways are secretagogues of 
insulin, and whether their actions are influenced by 
glucose in isolated rat islets. Our results indicate 
that LTC4 and hepoxilin A3 stimulate insulin release 
at a “basal” concentration of glucose, and, with the 
exception of LTC4, all lipoxygenase products tested 
inhibit glucose-induced insulin release. 
for 60 min at 37°C in an atmosphere of 95% O2 
and 5% COZ. Upon completion of the preincuba- 
tion, icosanoids or their vehicle (100% ethanol) ap- 
propriately diluted in a volume of 400/~1 and 
400 ~1 of buffer containing glucose to yield a final 
glucose concentration of either 5.6 mM or 23 mM 
were added to each test tube. The final concentra- 
tions of the icosanoids were: 12-(R)-HETE or 
12-(S)-HETE 10-M; 12-(S)-HPETE 10%; LTB4 l@ 
6M; LTC4 6x 10M7M; hepoxilin A3 lo-6M; and 
lipoxin B4 M. The l.O-ml samples were incubated 
for 30 min at 37°C. Thereafter, the tubes were 
chilled rapidly and centrifuged at 800 g for 3 min 
at 4°C. The supernatants were removed and stored 
at-20°C for subsequent measurement of the levels of 
insulin. 
MATERIALS AND METHODS 
The supplier of collagenase (type V) and Ficoll was 
Sigma, St. Louis, MO, and that of 12-(R)-HETE 12- 
(S)-HETE, 12-(S)-HPETE, LTB4, LTC4, hepoxilin 
As as methyl ester, and 5, 6, 15trihydroxy- 
icosatetraenoic acid (lipoxin BJ as methyl ester 
Cayman Chemical, Ann Arbor, MI. All icosanoids 
were shipped in dry ice in ethanol and were stored 
at -70°C. 
The levels of insulin in the incubation media 
were measured by a ‘double-antibody’ radioim- 
munoassay, in which a rat insulin antiserum and 
rat insulin standards were employed (17). The inter- 
assay variability was 6-9%. 
On the day of each experiment, pancreatic islets 
were isolated from 250 to 350-g male Wistar rats, 
which had free access to food and water until the 
time of the procedure. The method of Gotoh et al 
(16) was used, in which the digestion of the 
pancreas proceeded without shaking, followed by a 
density gradient and manual sorting of the islets. 
Ten islets were transferred into each test tube, 
At least three experiments of each kind were car- 
ried out, each time using a different batch of islets. 
Each experimental condition was run in triplicate. 
On each sample, the radioimmunoassay was carried 
out in duplicate, and the mean result of the repli- 
cates was computed. To accommodate the variation 
in insulin-secretory capacity among different batches 
of islets, the data for each experiment were normal- 
ized by setting the result obtained with 5.6 mM 
glucose alone to 100%. The means from all experi- 
ments of the same kind were used to obtain the 
mean &SEM for that test condition, The statistical 
significance of the differences among means was 
determined by analysis of variance using Dunnett’s 
tetesting. 
Table Immunoreactive insulin release from isolated rat islets in response to icosanoids formed in various lipoxygenase pathways, 
in the presence of low and high concentrations of glucose 
Icosanoid (N) 
Insulin Release (Mean + SEM Percent)* 
With 5.6 mM Glucose With 23 mM Glucose 
Icosanoid No Icosanoid Icosanoid 
LTB,; 1U6 M (3) 136 + 12 250 + 51t 130 * 19t 
LTC,; 6 x 1(r7 M 
;; 
304 + 32t 250 f 51t 162 + 15 
12-(S)-HPETE; 10” M 56 + 6-t 139 + 11t 50 f St 
12-(R)-HETE; 10” M 111 f 19 190 + lot 91 + 14t 
12-(S)-HETE; 10” M 104.5 + 6.6 190 2 lot 112 i 187 
Hepoxilin A,; lo” M 
Lipoxin B,; 10” M 
tz; 234 + 39t 320 f 33t 145 + 287 
(3) 106.4 + 12 320 + 33t 101 + 27t 
Footnotes: 
The final concentration of each icosanoid is given in parentheses next to its name. 
For each experimental condition, the number of observations is given in parentheses. 
[*] The data for each experiment were normalized by setting the result obtained with 5.6 mM glucose alone to 100%. 
[t] p<O.OS vs with 5.6 mM glucose alone. 
[t] p<O.O5 vs with 23 mM glucose alone. 
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RESULTS 
When the data from all experiments were compiled, 
over the 30-min incubation period, in the absence 
of any icosanoids, the secretion of insulin was 229 
+40&‘islet/h with 5.6 mM glucose and 410 f 55 
&islet/h with 23 mM glucose (N=13; ~~0.01). 
The data on the effects of individual icosanoids at 
the two concentrations of glucose are given in the 
Table. 
The effects of two 5-lipoxygenase pathway 
products were tested. Under basal conditions 
(5.6 mM glucose), LTC4 stimulated the release of 
insulin in the presence of 5.6 mM glucose; LTB4 
had a mild stimulatory effect which did not attain 
statistical significance. The stimulatory effect of 
LTC, exceeded that of LTB4 (304% KS 136%, p 
~0.05). LTC4 did not modify the release in 
response to 23 mM glucose; on the other hand, 
LTB, inhibited glucose-induced insulin release. 
Four 12-lipoxygenase pathway products were 
selected. 12-(S)-HPETE inhibited insulin release in 
the presence of 5.6 mM as well as 23 mM glucose. 
Neither 12-(R)-HETE nor 12-(S)-HETE had any ef- 
fect on basal insulin release. In the presence of 
23 mM glucose, 12-(R)-HETE as well as 12-(S)- 
HETE inhibited glucose-induced insulin release. 
Hepoxilin A3 stimulated insulin secretion in the 
presence of 5.6 mM glucose, but inhibited insulin 
release evoked by 23 mM glucose. 
Both 5-lipoxygenase and 15-lipoxygenase are in- 
volved in the biosynthesis of lipoxin. B4 Lipoxin had 
no effect on basal insulin secretion. It inhibited in- 
sulin release stimulated by 23 mM glucose. 
Statistical comparison of the insulin-secretory 
responses to individual lipoxygenase-pathway 
products in the presence of 5.6 mM glucose vs in 
the presence of 23 mM glucose did not reveal any 
significant differences. 
DISCUSSION 
Our results indicate that icosanoids formed in the 
lipoxygenase pathways affect insulin secretion in a 
complex manner. 
Since 5.6 mM is slightly below the blood level of 
glucose which prevails in the fasting rat, and since 
the islets had been exposed to this concentration 
during the 60-min preincubation followed by the 30- 
min incubation periods, we assumed that the insulin 
secreted with 5.6 mM glucose represented the 
‘basal’ secretion, and interpreted the response to 
an icosanoid at this concentration of glucose as an 
effect of that icosanoid on its own. 
Among the seven icosanoids representing the 
products formed in the three lipoxygenase path- 
ways, the 5-lipoxygenase product LTC, and the 
1Zlipoxygenase product hepoxilin As stimulated the 
basal secretion of insulin. In this regard, LTC4 was 
by far the more potent one, despite the fact that it 
was employed at a concentration lower than all 
other icosanoids. We reported previously that, in 
the perfused rat pancreas, in the presence of 
5.6 mM glucose, LTB4 as well as LTCa stimulate in- 
sulin secretion at similar potencies in a dose-related 
manner in the concentration range of lo-” M to 10e7 
M (10). In the present study, the mild stimulatory 
effect of LTB4, at a concentration higher than those 
employed previously, did not attain statistical sig- 
nificance. In addition to the obvious differences in 
the experimental conditions, the possibility of 
tachyphylaxis may be considered. Our observation 
of an agonist action of hepoxilin As in the presence 
of 5.6 mM glucose is an extension of that of Pace- 
Asciak and Martin (9) that hepoxilin stimulated 
insulin release at 10 mM glucose. 
Thus, to this date, among the lipoxygenase- 
pathway products, LTB4 and peptidyl LTs (10, and 
present study), 5-HETE (7); and hepoxilin A3 (9) 
have been shown to stimulate basal insulin secretion 
on their own. 
In our study, 12-(S)-HPETE inhibited the basal 
release of insulin. Metz et al (4) reported that 12- 
HPETE stimulated insulin release in neonatal rat 
islets, but had no effect in adult islets. The reasons 
for the age difference in the insulin-secretory 
responses observed by Metz, and the contrasting in- 
hibitory response which we observed remain to be 
clarified; differences in experimental conditions, or 
the fact that we used selectively the (S) enantiomer 
rather than an unspecified preparation of 12- 
HPETE may have affected the outcome. 
1ZHPETE is chemically unstable; conversion of 12- 
HPETE to another product in islets may be 
considered as being responsible for the inhibitory ef- 
fect. 12-HPETE‘ is the immediate precursor of 
12-HETE; reportedly, 12-HPETE can be converted 
also to hepoxilin in islets (9). Our results with ex- 
ogenous 12-HETEs or hepoxilin do not lend support 
to the possibility that these compounds mediated 
the inhibitory effect of 12-HPETE, in that 12-HETE 
had no effect on, and hepoxilin stimulated basal in- 
sulin release. Nevertheless, some other compound 
formed in islets from 1ZHPETE may have been 
responsible for the inhibition. 
Neither the (R) nor the (S) enantiomer of 12- 
HETE stimulated the basal secretion of insulin. In 
previous studies, 12-HETE preparations of un- 
known type had been used. We had considered that 
stereospecificity may be a determinant in any 
secretagogue action; for example, the (R) en- 
antiomer of 1ZHETE may interact with LTB4 
receptors (18). Still, the employment of the in- 
dividual enantiomers of 12-HETE failed to uncover 
an agonist action which previously may have been 
overlooked. 
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The effect of lipoxins on the secretion process 
previously had not been tested. Lipoxin B4 failed to 
affect basal insulin secretion. In the case of lipoxin, 
as well as in the case of the two enantiomers of 12- 
HETE, one may consider that they were inhibitory 
in the basal state, but that the model employed was 
not sufficiently sensitive to demonstrate the inhibi- 
tion. This is unlikely, since the inhibitory action of 
12-(S)-HPETE could be revealed. 
The striking novel finding in our study is that, 
with the exception of LTQ, all lipoxygenase path- 
way products employed exerted an inhibitory action 
on insulin release, when insulin release had been 
augmented in the presence of 23 mM glucose. In 
most cases, these icosanoids suppressed insulin 
release toward or to, but not below the levels ob- 
served in the presence of 5.6 mM glucose alone. 
Hence, we believe that the lipoxygenase products 
interfered with the stimulatory signal for insulin 
secretion elicited by glucose, irrespective of 
whether, on their own, they may have a stimulatory 
or inhibitory effect, or no effect on insulin release. 
An extrapolation of our findings with exogenous 
lipoxygenase-pathway products to their endogenous 
counterparts would assign to the latter a negative 
rather than a positive modulatory role in glucose- 
induced insulin release. Since glucose promotes the 
biosynthesis of icosanoids in islets, including the 
lipoxygenase pathway products, the intriguing possi- 
bility emerges that, by inducing the increased 
availability of these compounds, glucose engages a 
restraining system on insulin release. 
LTC4 stimulated basal insulin release and had no 
effect on glucose-induced insulin release. In the case 
of hepoxilin, the stimulation of basal, but inhibition 
of glucose-induced insulin release are seemingly 
paradoxical. These icosanoids may have two or 
more mechanisms of action in the islet B-cells. One 
mechanism may provide for a tonic-stimulatory in- 
fluence, while another may interfere selectively with 
the signal for insulin release generated by glucose. 
The latter mechanism may have mitigated the 
strong agonist action LTC4 only partially, while it 
may have overwhelmed the action of the weaker 
agonist hepoxilin. In this regard, the lipoxygenase 
products are not unique. The promotion of the 
basal secretion of insulin by prostaglandins has been 
observed repeatedly (19-21); yet, others reported 
that the same icosanoids inhibited glucose-induced 
insulin release (20, 22). 
The results of our study, as well as those of pre- 
vious work by others, do not proyide an explanation 
for the consistent observation that nonselective in- 
hibitors of lipoxygenases inhibit stimulated insulin 
release. All drugs are likely to have actions in ad- 
dition to the main action attributed to them; hence, 
these compounds may be inhibiting insulin release 
by mechanisms unrelated to the inhibition of 
lipoxygenases. The fact that chemically unrelated 
lipoxygenase inhibitors have the same effect 
weakens this possibility. Another possibility is that 
the inhibition of lipoxygenases may lead to in- 
creased production in alternate pathways of certain 
arachidonate metabolites that could be inhibitors of 
stimulated insulin release. A third possibility is that 
other icosanoids formed in islets in the lipoxygenase 
pathways, the identity of which is obscure at this 
time, may have tonic-stimulatory properties without 
interfering with the glucose signal, the formation of 
which is inhibited by the lipoxygenase inhibitors. 
We conclude that, among the lipoxygenase 
products tested, only leukotrienes and hepoxilin are 
candidates for a tonic-stimulatory influence on basal 
insulin release. Our observation that lipoxygenase 
products inhibited glucose-induced insulin release, 
together with the existing evidence that glucose aug- 
ments icosanoid formation in pancreatic islets, 
suggest the existence in islets of a negative-feedback 
system involving these icosanoids, 
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